


---

<b>Product Name</b>	: ACT-1004-1239
<b>Cat. No.</b>	: PC-72634
<b>CAS No.</b>	: 2178049-58-4
<b>Molecular Formula</b>	: C <sub>27</sub> H <sub>28</sub> F <sub>2</sub> N <sub>6</sub> O <sub>3</sub>
<b>Molecular Weight</b>	: 522.557
<b>Target</b>	: Chemokine Receptor (CCR and CXCR)
<b>Solubility</b>	: 10 mM in DMSO



## Biological Activity

ACT-1004-1239 is a potent, selective, orally available **CXCR7** antagonist with IC<sub>50</sub> of 3.2 nM (hCXCR7).

ACT-1004-1239 also shows similar potency against rat, mouse and dog CXCR (IC<sub>50</sub>=2-3 nM), shows high selectivity in a panel of 87 enzymatic and radioligand binding assays (CXCR4, IC<sub>50</sub>>10 uM).

ACT-1004-1239 is a potent insurmountable CXCR7 antagonist against both CXCL11 and CXCL12, shows a dose-dependent increase of CXCL12 plasma concentration in mice.

## References

Sylvia Richard-Bildstein, et al. *J Med Chem.* 2020 Dec 24;63(24):15864-15882.

Huynh C, et al. *Clin Pharmacol Ther.* 2021 Jun;109(6):1648-1659.

Huynh C, et al. *Biomed Pharmacother.* 2021 Dec;144:112363.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com

---